WT1 Peptid Vaccination in Carcinomas

Phase II Study of WT1 126-134 Peptide Vaccination in Combination With Adjuvants GM-CSF and KLH in Carcinomas

In this trial HLA-A2+ patients with WT1 expressing carcinomas are vaccinated with a peptide from the leukemia associated antigen WT1 together with immunological adjuvants KLH as T-helper protein and GM-CSF

Inclusion Criteria:

• Metastatic cancer, no standard treatment option
• Resected cancer with minimal residual disease, no standard treatment option
• WT-1 expression
• HLA-A2

Exclusion Criteria:

• Concurrent chemotherapy